# åˆ¶è¯æ—¥æŠ¥ Pharma Daily

**æ—¥æœŸ**: 2026-01-21
**æ›´æ–°æ—¶é—´**: 2026-01-22 04:41
**æ–°é—»æ•°é‡**: 103

---

## ä»Šæ—¥æ¦‚è§ˆ

## ğŸ“Š AI æ™ºèƒ½åˆ†æ

### ä»Šæ—¥æ¦‚è§ˆ

ä»Šæ—¥åˆ¶è¯è¡Œä¸šåŠ¨æ€èšç„¦äºå¤§å‹è¯ä¼çš„æˆ˜ç•¥è°ƒæ•´ä¸é‡ç£…äº¤æ˜“ã€‚è¾‰ç‘ä»¥19äº¿ç¾å…ƒå‡ºå”®å…¶åœ¨GSKæ——ä¸‹ViiV Healthcareçš„è‚¡ä»½ï¼ŒGSKåˆ™ä»¥22äº¿ç¾å…ƒæ”¶è´­RAPT Therapeuticsä»¥åŠ å¼ºå…¶è¿‡æ•è¯ç‰©ç®¡çº¿ã€‚åŒæ—¶ï¼Œå¼ºç”Ÿé¢„è®¡2026å¹´è¥æ”¶å°†çªç ´1000äº¿ç¾å…ƒï¼Œä¸»è¦å¾—ç›Šäºå…¶æ˜æ˜Ÿäº§å“Darzalexçš„å¼ºåŠ²å¢é•¿ã€‚

### ğŸ”¥ é‡ç‚¹æ–°é—»

**1. Pfizer sells its stake in GSK's ViiV for $1.9B, with Shionogi upping its ante in the HIV-focused company** â­â­â­â­â­
   - ç±»åˆ«: å•†ä¸šåŠ¨æ€
   - è¾‰ç‘å‡ºå”®å…¶æŒæœ‰çš„ViiVè‚¡ä»½ï¼Œæ¶‰åŠé‡‘é¢å·¨å¤§ï¼Œæ ‡å¿—ç€å…¶åœ¨HIVé¢†åŸŸæˆ˜ç•¥çš„é‡å¤§è°ƒæ•´ã€‚

**13. GSK to buy Rapt in $2.2B deal for food allergy drug** â­â­â­â­â­
   - ç±»åˆ«: å•†ä¸šåŠ¨æ€
   - GSKä»¥22äº¿ç¾å…ƒæ”¶è´­RAPT Therapeuticsï¼Œæ˜¯å…¶æ–°ä»»CEOçš„é¦–ç¬”é‡å¤§äº¤æ˜“ï¼Œæ—¨åœ¨åŠ å¼ºå…¶è¿‡æ•è¯ç‰©ç®¡çº¿ã€‚

**6. Led by Darzalex surge, J&J expects revenue to reach $100B in 2026** â­â­â­â­â­
   - ç±»åˆ«: å¸‚åœºåˆ†æ
   - å¼ºç”Ÿé¢„è®¡2026å¹´è¥æ”¶å°†çªç ´1000äº¿ç¾å…ƒï¼Œå…¶æ˜æ˜Ÿäº§å“Darzalexçš„å¼ºåŠ²å¢é•¿æ˜¯å…³é”®é©±åŠ¨åŠ›ã€‚

**4. IntraBio's Aqneursa, on a roll with EU approval, races toward another rare disease indication with phase 3 win** â­â­â­â­
   - ç±»åˆ«: ä¸´åºŠè¯•éªŒ
   - IntraBioçš„Aqneursaåœ¨ç½•è§ç—…é¢†åŸŸå–å¾—å…³é”®IIIæœŸè¯•éªŒæˆåŠŸï¼Œå¹¶å·²è·å¾—æ¬§ç›Ÿæ‰¹å‡†ï¼Œæ˜¾ç¤ºå‡ºå…¶åœ¨ç½•è§ç—…æ²»ç–—é¢†åŸŸçš„æ½œåŠ›ã€‚

**9. Valneva withdraws chikungunya vaccine Ixchiq from US amid new FDA investigation** â­â­â­â­
   - ç±»åˆ«: ç›‘ç®¡å®¡æ‰¹
   - Valnevaå› FDAè°ƒæŸ¥è€Œè‡ªæ„¿æ’¤å›å…¶åŸºå­”è‚¯é›…çƒ­ç–«è‹—ï¼Œæ¶‰åŠé‡å¤§äº§å“å®‰å…¨ä¸ç›‘ç®¡é—®é¢˜ã€‚

### ğŸ“ åˆ†ç±»æ‘˜è¦

**æ–°è¯ç ”å‘** (Drug R&D): ä»Šæ—¥æ–°è¯ç ”å‘åŠ¨æ€è¾ƒå°‘ï¼Œä½†IntraBioçš„Aqneursaåœ¨ç½•è§ç—…é¢†åŸŸå–å¾—è¿›å±•ï¼Œä»¥åŠCorvusçš„æ¹¿ç–¹å£æœè¯æ—©æœŸæ•°æ®ç§¯æï¼Œæ˜¾ç¤ºå‡ºæ–°é¶ç‚¹ï¼ˆå¦‚ITKæŠ‘åˆ¶å‰‚ï¼‰çš„æ½œåŠ›ã€‚
**ä¸´åºŠè¯•éªŒ** (Clinical Trials): IntraBioå®£å¸ƒå…¶æ²»ç–—Ataxia-Telangiectasiaçš„è¯ç‰©åœ¨å…³é”®IIIæœŸè¯•éªŒä¸­æˆåŠŸæ”¹å–„è¿åŠ¨åŠŸèƒ½ï¼Œæ˜¯ä»Šæ—¥æœ€çªå‡ºçš„ä¸´åºŠè¯•éªŒè¿›å±•ã€‚

### ğŸ”® æ˜æ—¥å…³æ³¨

å€¼å¾—å…³æ³¨FDAå¯¹Valnevaç–«è‹—è°ƒæŸ¥çš„è¿›ä¸€æ­¥è¿›å±•ã€GSKæ”¶è´­RAPTäº¤æ˜“çš„åç»­ç»†èŠ‚ï¼Œä»¥åŠå¼ºç”Ÿç­‰å…¬å¸åŸºäºDarzalexç­‰äº§å“å¯¹æœªæ¥å¸‚åœºçš„å…·ä½“é¢„æµ‹å’Œæˆ˜ç•¥è§„åˆ’ã€‚


---

## æ•°æ®ç»Ÿè®¡

| ç±»åˆ« | æ•°é‡ |
|------|------|
| ç»¼åˆ (ç»¼åˆ) | 40 |
| æ–°è¯ç ”å‘ (Drug R&D) | 34 |
| ç›‘ç®¡å®¡æ‰¹ (Regulatory) | 20 |
| å•†ä¸šåŠ¨æ€ (Business/M&A) | 9 |

---

## ç»¼åˆ | ç»¼åˆ

### ğŸ‡ºğŸ‡¸ Pfizer sells its stake in GSK's ViiV for $1.9B, with Shionogi upping its ante in the HIV-focused company

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-20 09:29
- **é‡è¦æ€§**: â­â­â­â­

> Five weeks after telling investors to expect a revenue decline in 2026, Pfizer has found a quick funding fix, selling off its stake in GSKâ€™s ViiV Healthcare. The New York powerhouse has agreed to surrender its 11.7% interest in the HIV-focused company for $1.875 billion. Under terms of the agreement, Shionogi will pick up Pfizerâ€™s shares for $2.125 billion, with GSK gaining a special dividend of $250 million.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/pfizer-sells-its-stake-gsks-viiv-19b-shionogi-upping-its-ante-hiv-focused-company)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about antitrust claims by a compounder, FDA and EMA AI rules, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-15 14:12
- **é‡è¦æ€§**: â­â­â­â­

> The FDA delayed reviews of two drugs chosen for the Trump administration's new fast-track program after agency scientists flagged safety and efficacy concerns

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/15/fda-antitrust-lilly-novo-compounders-insulin-ai-novartis/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ IntraBio's Aqneursa, on a roll with EU approval, races toward another rare disease indication with phase 3 win

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-21 11:04
- **é‡è¦æ€§**: â­â­â­

> The company announced a phase 3 win in the rare neurodegenerative disease Ataxia-Telangiectasia on the same day it snagged a key European approval in the drug's original indication of Niemann-Pick disease type C.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/intrabios-aqneursa-roll-eu-approval-races-toward-another-rare-disease-indication-phase-3-win)

---

### ğŸ‡ºğŸ‡¸ Led by Darzalex surge, J&amp;J expects revenue to reach $100B in 2026

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-21 11:20
- **é‡è¦æ€§**: â­â­

> Led by cancer standout Darzalex, Johnson &amp; Johnson projects that its 2026 revenue will reach between $100 billion and $101 billion. With J&amp;J also forecasting double-digit revenue increases by the end of the decade, the drugmaker may be on its way to kicking off a $100-billion-plus annual revenue streak.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/led-darzalex-surge-jj-expects-revenue-reach-100b-2026)

---

### ğŸ‡ºğŸ‡¸ Definium defines mental health applications for LSD in new awareness campaign

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-20 11:30
- **é‡è¦æ€§**: â­â­

> As it inches closer to FDA submissions for its psychedelic drug candidate, Definium Therapeutics is laying the groundwork for a future launch with an educational push about the pharmaceutical potential of LSD.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/definium-defines-mental-health-applications-lsd-new-awareness-campaign)

---

### ğŸ‡ºğŸ‡¸ Roche scales Genentechâ€™s North Carolina site to $2B in major obesity market play

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-20 11:47
- **é‡è¦æ€§**: â­â­

> Roche is more than doubling its total commitment to a future facility for its Genentech unit to approximately $2 billion. The plant, being built in Holly Springs, North Carolina, will be used to crank out next-generation drugs for metabolic conditions like obesity, Roche has said.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/manufacturing/roche-beefs-investment-genentechs-future-nc-obesity-drug-factory-2b)

---

### ğŸ‡ºğŸ‡¸ Valneva withdraws chikungunya vaccine Ixchiq from US amid new FDA investigation

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-20 09:53
- **é‡è¦æ€§**: â­â­

> Following an FDA marketing suspension, Valneva has decided to voluntarily withdraw its chikungunya vaccine Ixchiq in the U.S. The FDA has also opened an investigation into a newly reported serious adverse event.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/valneva-withdraws-chikungunya-vaccine-ixchiq-us-amid-new-fda-investigation)

---

### ğŸ‡ºğŸ‡¸ Drug approvals went from crawl to sprint in 2025

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-15 16:37
- **é‡è¦æ€§**: â­â­

> On this episode of "The Top Line," we dig into how turmoil at the FDA impacted drug approvals in 2025.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/drug-approvals-went-crawl-sprint-2025)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about Canada speeding drug reviews, Novo Nordisk ads, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-21 14:14
- **é‡è¦æ€§**: â­â­

> Health Canada is planning to speed up reviews of some drugs by piggybacking on the decisions of foreign regulators, including possibly the U.S. FDA

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/21/canada-vaccines-novo-eczema-diabetes/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: GSK to buy RAPT Therapeutics, maker of food allergy treatment, in $2.2B deal

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-20 08:01
- **é‡è¦æ€§**: â­â­

> GSK is buying RAPT Therapeutics in a deal worth $2.2 billion, picking up an experimental medicine for food allergies.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/20/gsk-rapt-therapeutics-acquisition-food-allergy-prophylaxis-ozureprubart/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: FDA delays reviews for two drugs in new voucher program

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-16 14:36
- **é‡è¦æ€§**: â­â­

> And more biotech news, brought to you by The Readout

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/16/biotech-news-fda-delays-review-in-voucher-program/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about FDA voucher worries, weight loss drugs and jet fuel, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-16 14:30
- **é‡è¦æ€§**: â­â­

> Some major drugmakers are hesitating to participate in the Trump administration's speedier review program for new medicines over possible legal risks

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/16/trump-fda-voucher-obesity-novo-lilly-covid/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ Single-drug Exelixis aims to be top 5 solid tumor company in the US: CEO

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-16 10:16
- **é‡è¦æ€§**: â­

> Exelixis may only have one drug on the market right now, but with phase 3 results for a potential new blockbuster on the horizon and a growing pipeline, the Cabometyx maker is aiming big.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/single-product-exelixis-aims-be-top-5-solid-tumor-drugmaker-us)

---

### ğŸ‡ºğŸ‡¸ In J&amp;J talc litigation, N.J. court-appointed official recommends allowing expert testimony

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-21 15:13

> In Johnson &amp; Johnson's long-running talc litigation, a court-appointed special master has recommended that plaintiffs should be able to present testimony from expert witnesses who can speak to scientific evidence backing their claims. The decision could negatively impact the company's defense of lawsuits from those who claim Johnsonâ€™s Baby Powder caused their cancer.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/jj-talc-litigation-nj-court-recommends-allow-expert-testimony)

---

### ğŸ‡ºğŸ‡¸ UPDATE: In quick reversal, Trump calls off tariff threat related to Greenland pursuit

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-20 09:55

> Only a few days after threatening to impose new tariffs on a group of European countries related to his pursuit of Greenland, the president has called off the threat.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/trumps-new-tariff-threats-around-greenland-threaten-upend-eu-trade-deal)

---

### ğŸ‡ºğŸ‡¸ Pfizer CEO lays blame for US vaccine woes on RFK Jr.'s 'anti-science' stance: WSJ

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-21 09:46

> While much of the biopharma industry has spent the past 12 months treading lightly around the Trump administration and the tumult it has wrought on U.S. medical research and regulation, Pfizerâ€™s CEO cut to the chase this week in a blatant rebuke of HHS Secretary Robert F. Kennedy Jr., according to The Wall Street Journal.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/pfizer-ceo-lays-blame-us-vaccine-woes-anti-science-rfk-jr-wsj)

---

### ğŸ‡ºğŸ‡¸ Rising Stars: Regeneronâ€™s Catie Matthews on updating marketing strategy to meet the AI boom

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-20 12:30

> In a Q&amp;A for Fierce Pharma Marketingâ€™s â€œRising Starsâ€ series, Catie Matthews suggested that marketers should embrace artificial intelligence in their own lives.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/rising-stars-regenerons-catie-matthews-updating-marketing-strategy-amid-ai-boom)

---

### ğŸ‡ºğŸ‡¸ GSK licenses Alteogen enzyme in bid to develop subQ Jemperli

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-20 14:08

> GSK, through its oncology subsidiary Tesaro, is handing over $20 million upfront to Alteogen for global rights to the Korean biotechâ€™s novel hyaluronidase ALT-B4. Tesaro plans to use ALT-B4 to develop and potentially market a subcutaneous form of the ascendant cancer med Jemperli.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/gsk-offers-alteogen-285m-subq-jemperli-licensing-pact)

---

### ğŸ‡ºğŸ‡¸ Takeda's neuroscience field force hit with layoffs as key patent loss looms for Trintellix

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-20 13:14

> Takeda is executing another round of layoffs, cutting 243 roles in the United States. The company is preparing for an upcoming patent loss on depression drug Trintellix.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/takeda-cuts-243-us-workers-generic-competition-looms-trintellix)

---

### ğŸ‡ºğŸ‡¸ Supreme Court agrees to review 'skinny label' battle between Hikma, Amarin over generic Vascepa

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-20 11:27

> The U.S. Supreme Court will hear a case involving the "skinny label" practice of generic drugmakers, with its review particularly relating to Hikma's marketing of its generic version of Amarin's Vascepa.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/supreme-court-agrees-review-skinny-label-battle-hikma-amarin-over-generic-vascepa)

---

### ğŸ‡ºğŸ‡¸ Curia's Mass. plant closure to eliminate 81 jobs

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-20 17:08

> Curia Global is laying off 81 employees as part of its plan to shut down its drug product development and manufacturing facility in Burlington, Massachusetts, according to a Worker Adjustment and Retraining Notification.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/manufacturing/curia-plant-shutdown-massachusetts-forces-lay-81)

---

### ğŸ‡ºğŸ‡¸ Apiject signs lease for new generics blow-fill-seal manufacturing facility in N.C.

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-20 08:33

> Prefilled drug delivery device specialist Apiject has signed a lease for a new site in Apex, North Carolina, that will house two blow-fill-seal production lines.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/manufacturing/apiject-signs-lease-new-generics-blow-fill-seal-facility-north-carolina)

---

### ğŸ‡ºğŸ‡¸ Novo riffs on Appleâ€™s â€˜Get a Macâ€™ ads in Ozempic push starring Justin Long, John Hodgman

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-16 15:28

> Amid a viral social media trend glorifying the halcyon days of 2016, Novo Nordisk has gone back an extra decade to find inspiration for its latest direct-to-consumer Ozempic campaign.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/novo-riffs-apples-get-mac-ads-ozempic-push-starring-justin-long-john-hodgman)

---

### ğŸ‡ºğŸ‡¸ From approval to value: Why evidence storytelling now matters

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-15 15:46

> RTI Health Solutions experts explain how HEOR and real-world evidence are reshaping access decisionsâ€”and why clear communication is essential.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/sponsored/approval-value-why-evidence-storytelling-now-matters)

---

### ğŸ‡ºğŸ‡¸ After AbbVie and Genmab's ph. 3 survival miss for Epkinly in DLBCL, what's next?

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-16 15:29

> Just days after AbbVie unveiled a major new oncology play in the form of its high-dollar RemeGen collab, the Illinois drugmaker closed out the week with some mixed news for marketed cancer offering Epkinly.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/after-abbvie-and-genmabs-ph-3-survival-miss-epkinly-dlbcl-whats-next)

---

### ğŸ‡ºğŸ‡¸ JPM26: Fujifilm CEO touts biologics capacity edge amid expansion tear

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-16 10:52

> With Fujifilm Biotechnologies now among the top echelon of CDMOs by biologics capacity, Fujifilmâ€™s group CEO reflected on the unitâ€™s unique facility design philosophy and how itâ€™s eschewing big M&amp;A plays to expand in-house.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/jpm26-fujifilm-ceo-touts-biologics-capacity-edge-manufacturing-unit-keeps-expansions-coming)

---

### ğŸ‡ºğŸ‡¸ AbbVieâ€™s Skyrizi takes full-year TV ad spending crown yet again, with J&amp;Jâ€™s Tremfya in hot pursuit

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-16 10:49

> For the fourth year runningâ€”and the third in a row for Skyrizi specificallyâ€”an AbbVie immunology med has claimed the top spot in the full-year TV drug ad spending rankings.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/abbvies-skyrizi-takes-full-year-tv-ad-spending-crown-yet-again-jjs-tremfya-hot-pursuit)

---

### ğŸ‡ºğŸ‡¸ Fierce Pharma Asiaâ€”AbbVieâ€™s bispecific play, Illuminaâ€™s China import efforts and pharma execsâ€™ JPM comments

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-15 10:47

> In this week's Asia news recap, AbbVie struck a big deal to enter the hot PD-1xVEGF bispecific space, while Illumina's CEO detailed the company's efforts to work with authorities in China. In addition, Astellas CEO Naoki Okamura updated the audience at Fierce JPM Week on the company's approach to dealmaking.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/fierce-pharma-asia-abbvies-bispecific-play-illuminas-china-import-efforts-and-pharma-execs)

---

### ğŸ‡ºğŸ‡¸ Former Emergent CEO Kramer faces insider trading allegations in NY

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-15 16:21

> New York's attorney general has filed an insider trading lawsuit against former Emergent BioSolutions CEO Robert Kramer, accusing him of selling company shares and receiving more than $10 million before the company revealed contamination issues at a plant in Baltimore. As part of the action, New York also announced a $900,000 million settlement with the company.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/former-emergent-ceo-kramer-faces-insider-trading-allegations-ny)

---

### ğŸ‡ºğŸ‡¸ STAT+: Novo strikes deal for diabetes cell therapies

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-21 14:53

> And other biotech news, brought to you by The Readout newsletter

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/21/biotech-news-novo-nordisk-acquires-aspect-biosystems/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ Congress revives health care deal with PBM reforms

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-20 15:31

> This is the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and medicine.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/20/congress-revives-health-care-deal-pbm-reforms-dc-diagnosis-newsletter/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Benefit from Modernaâ€™s skin cancer immunotherapy endures

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-20 14:47

> And other biotech news brought to you by the Readout Newsletter

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/20/biotech-news-moderna-merck-skin-cancer-mrna/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about drug prices in Europe, a cancer vaccine, and much more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-20 14:20

> U.S. pharmaceutical companies are stepping up their campaign for higher drug prices in Europe, in some cases threatening to withhold new medicines

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/20/pharma-prices-china-gsk-aids-cancer-vaccine-europe/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Florida proposes cutting eligibility for an AIDS drug program, causing panic

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-20 09:30

> In a surprise move, Florida officials have proposed drastically reducing eligibility for the state AIDS drug assistance program.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/20/florida-hiv-aids-gilead-health-insurance/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Congress revives bipartisan health care proposal, including drug middlemen provisions

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-20 01:03

> Elements of a health care deal that was blown up by Elon Musk are getting a fresh look in Congress.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/19/bipartisan-health-care-package-pharmacy-benefit-manager/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Supreme Court agrees to review â€˜skinny labelingâ€™ and generic drug access

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-16 21:03

> The Supreme Court agreed to review a controversy over so-called skinny labels for medicines, a decision that will be closely watched for its implications for the availability of generic medicines.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/16/scotus-generics-patents-supreme-court-amarin-hikma/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Up and down the ladder: The latest comings and goings

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-16 17:00

> From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/16/pharma-biotech-jobs-novo-bristol-astrazeneca/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Trump releases health care plan amid pressure over affordability

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-15 18:10

> Trump's most consequential proposals would require action from Congress.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/15/trump-great-healthcare-plan-potential-stumbling-blocks/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Former Emergent BioSolutions CEO sued for insider trading, company reaches $900K settlement in N.Y.

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-15 17:55

> The former CEO of Emergent BioSolutions was accused of insider trading by the New York attorney general in connection with a Covid-era contract.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/15/covid-insider-trading-stock-emergent-astrazeneca/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmacy compounder files antitrust lawsuit against Eli Lilly and Novo Nordisk

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-15 01:29

> A compounding pharmacy has filed a lawsuit accusing Eli Lilly and Novo Nordisk of using anticompetitive tactics to prevent it from serving patients.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/14/pharmacy-compounder-antitrust-lilly-novo-weight-obesity/?utm_campaign=rss)

---

## æ–°è¯ç ”å‘ | Drug R&D

### ğŸ‡ºğŸ‡¸ J&J praises new FDA guidance to speed development of multiple myeloma drugs

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-21 18:35
- **é‡è¦æ€§**: â­â­â­â­

> Johnson &amp; Johnson, which has several drugs approved for multiple myeloma, praised the FDA's just-released draft guidance on how the agency will allow the use of minimal residual disease as a primary endpoint for accelerated ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/jj-praises-new-fda-guidance-to-speed-development-of-multiple-myeloma-drugs/)

---

### ğŸ‡ºğŸ‡¸ IntraBio says rare disease drug passes Phase 3, will seek FDA approval

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-21 16:05
- **é‡è¦æ€§**: â­â­â­

> IntraBio said Wednesday that its treatment improved motor function for a rare genetic disorder called ataxia-telangiectasia as part of a pivotal study. The Austin, TX-based biotech told Endpoints News it plans to submit an application ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/intrabio-says-rare-disease-drug-passes-phase-3-will-seek-fda-approval/)

---

### ğŸ‡ºğŸ‡¸ Corvus shares nearly triple on positive data for eczema pill

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-21 16:39
- **é‡è¦æ€§**: â­â­

> While early, the results indicate drugs known as ITK inhibitors have the potential to match or surpass the efficacy observed with the injectable biologic Dupixent.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/corvus-soquelitinib-phase-1-data-eczema-pill/810080/)

---

### ğŸ‡ºğŸ‡¸ Valneva to withdraw Chikungunya vaccine from US amid safety woes

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-20 16:47
- **é‡è¦æ€§**: â­â­

> The decision comes months after the FDA had suspended the vaccine&rsquo;s license. One analyst speculated the company might shelve the product altogether.&nbsp;

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/valneva-fda-withdrawl-application-chikungunya-Ixchiq-vaccine/809994/)

---

### ğŸ‡ºğŸ‡¸ GSK to buy Rapt in $2.2B deal for food allergy drug

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-20 15:57
- **é‡è¦æ€§**: â­â­

> The deal is the first for new CEO Luke Miels as the British drugmaker looks to overcome pressure on its HIV and vaccines businesses.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/gsk-rapt-acquire-food-allergy-prophylaxis-drug-ozureprubart/809956/)

---

### ğŸ‡ºğŸ‡¸ Kaileraâ€™s Ron Renaud on how a China-linked startup can compete in obesity

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-20 12:00
- **é‡è¦æ€§**: â­â­

> In an interview with BioPharma Dive, the veteran biotech CEO said there remains a &ldquo;significant opportunity&rdquo; for young companies in a market dominated by Novo Nordisk and Eli Lilly.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/kailera-ron-renaud-obesity-hengrui-rebupatide/809798/)

---

### ğŸ‡ºğŸ‡¸ When every day counts: Building CRO partnerships on a foundation of trust, care and precision

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-20 10:00
- **é‡è¦æ€§**: â­â­

> Clinical trial delays impact outcomes. Learn why CROs need a supply chain partner they can trust to reduce delays and help patients.&nbsp;

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/spons/when-every-day-counts-building-cro-partnerships-on-a-foundation-of-trust/809569/)

---

### ğŸ‡ºğŸ‡¸ Wegovy pill off to a fast start; Ex-Emergent CEO sued for insider trading

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-16 16:24
- **é‡è¦æ€§**: â­â­

> More than 3,000 prescriptions were written for Novo&rsquo;s GLP-1 pill in its first week on the market. Elsewhere, Emergent reached a settlement over a trading scandal and Sanofi is reportedly circling an eye drug biotech.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/wegovy-pill-sales-emergent-sanofi-ocular-jazz-novo/809709/)

---

### ğŸ‡ºğŸ‡¸ Government funding bill features PBM reforms, voucher reauthorization

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-20 19:14
- **é‡è¦æ€§**: â­â­

> The House is set to vote this week on a bipartisan bill to keep the government open beyond Jan. 30, with new proposals to change how pharmacy benefit managers operate and to reauthorize a lapsed ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/government-funding-bill-features-pbm-reforms-voucher-reauthorization/)

---

### ğŸ‡ºğŸ‡¸ Pfizer to depart GSK's ViiV as Shionogi doubles its stake

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-20 12:02
- **é‡è¦æ€§**: â­â­

> Pfizer is walking away from a specialist HIV company it created together with GSK more than a decade ago, with Shionogi taking its place. The Japanese drugmaker will buy about $2.13 billion worth of new ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/pfizer-to-depart-gsks-viiv-as-shionogi-doubles-its-stake/)

---

### ğŸ‡ºğŸ‡¸ GSK makes $2.2B deal for RAPT and its food allergy candidate

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-20 10:34
- **é‡è¦æ€§**: â­â­

> The biopharma industry was hungry for an M&amp;A deal during last weekâ€™s JP Morgan Healthcare Conference. It's finally getting one. GSK is scooping up RAPT Therapeutics for $2.2 billion, with a $1.9 billion upfront investment ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/gsk-makes-2-2b-deal-for-rapt-and-its-food-allergy-candidate/)

---

### ğŸ‡ºğŸ‡¸ Agomab and SpyGlass file for IPOs as investor enthusiasm builds after JPM

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-16 22:05
- **é‡è¦æ€§**: â­â­

> SpyGlass Pharma and Agomab Therapeutics filed for initial public offerings on Friday evening. The drug developers hope to build on the strong start set by Aktis Oncologyâ€™s $318 million Nasdaq listing last ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/agomab-and-spyglass-file-for-ipos-as-investor-enthusiasm-builds-after-jpm/)

---

### ğŸ‡ºğŸ‡¸ Fosun-funded Hygtia Therapeutics licenses Insilicoâ€™s NLRP3 inhibitor for Parkinsonâ€™s

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-21 12:14
- **é‡è¦æ€§**: â­

> A biotech funded by Shanghai Fosun Pharmaceutical is licensing a preclinical asset developed by Insilico Medicine in the NLRP3 space, which has garnered industry interest in recent months. Hygtia Therapeutics will get half the global ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/fosun-funded-hygtia-therapeutics-licenses-insilicos-nlrp3-inhibitor-for-parkinsons/)

---

### ğŸ‡ºğŸ‡¸ Corvus' new Phase 1 atopic dermatitis data meet high expectations

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-20 12:00
- **é‡è¦æ€§**: â­

> Corvus Pharmaceuticalsâ€™ therapy for severe atopic dermatitis is heading to mid-stage trials this quarter following an update from an ongoing Phase 1 study that met analysts' best-case scenario. The company's share price {$CRVS} soared more ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/corvus-new-phase-1-atopic-dermatitis-data-meet-high-expectations/)

---

### ğŸ‡ºğŸ‡¸ Exciva raises $59M Series B to fund Phase 2 test of Alzheimerâ€™s agitation drug

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-20 06:30
- **é‡è¦æ€§**: â­

> Exciva has secured â‚¬51 million ($59 million) in a Series B raise to advance its candidate for a common behavioral symptom of Alzheimerâ€™s disease into mid-stage development. The German biotech will use the proceeds to ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/exciva-raises-59m-series-b-to-fund-phase-2-test-of-alzheimers-agitation-drug/)

---

### ğŸ‡ºğŸ‡¸ AbbVie, Genmab say Epkinly didn't prolong overall survival in lymphoma study

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-16 21:01
- **é‡è¦æ€§**: â­

> AbbVie and Genmabâ€™s cancer drug Epkinly failed to improve overall survival in a late-stage study for diffuse large B cell lymphoma. The Phase 3 trial enrolled patients who had received at least one prior therapy ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/abbvie-genmab-say-epkinly-didnt-prolong-overall-survival-in-lymphoma-study/)

---

### ğŸ‡ºğŸ‡¸ J&J eyes $100B in sales amid gains for cancer, immune drugs

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-21 16:04

> Amid patent expirations, litigation and tariff costs, J&amp;J says it expects more growth ahead, fueled in part by its blood cancer medicines and a closely watched psoriasis pill.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/johnson-johnson-2025-earnings-sales-cancer-immune-drugs/810097/)

---

### ğŸ‡ºğŸ‡¸ Moderna cancer vaccine holds up; IO Biotech considers a sale

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-21 15:38

> Long-term data suggest Moderna&rsquo;s personalized melanoma shot provides &ldquo;durable tumor control,&rdquo; one analyst said. Elsewhere, Insilico Medicine partnered with a startup on a popular drug target.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/moderna-melanoma-io-biotech-nlrp3-think-pfizer-novavax/809958/)

---

### ğŸ‡ºğŸ‡¸ The patient retention crisis is happening before enrollment even begins

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-20 10:00

> The biggest patient drop-off happens before patients ever enroll.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/spons/the-patient-retention-crisis-is-happening-before-enrollment-even-begins/809568/)

---

### ğŸ‡ºğŸ‡¸ On biotechâ€™s biggest stage, renewed excitement gets a stress test

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-16 11:43

> A surge in deals and financings had the industry abuzz heading into this year&rsquo;s J.P. Morgan Healthcare Conference. But some aren&rsquo;t sure if the rebound is here to stay.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/jpm26-biotech-startups-deals-venture-ipo-fda-china/809809/)

---

### ğŸ‡ºğŸ‡¸ The status of EU drug price talks depends on who you ask

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-21 20:33

> One of the main questions for drugmakers entering 2026, and one they hope tilts in their favor, is whether the US will successfully pressure Europe to raise the price it pays for drugs. Three weeks ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/the-status-of-eu-drug-price-talks-depends-on-who-you-ask/)

---

### ğŸ‡ºğŸ‡¸ Johnson & Johnson brushes off MFN impact, sees strong growth for 2026

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-21 16:43

> As the calendar turns from JPM to quarterly reports, earnings bellwether Johnson &amp; Johnson makes its return for 2026. The focus this time? How biopharma will react to a slate of most favored nation deals ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/johnson-johnson-brushes-off-mfn-impact-sees-strong-growth-for-2026/)

---

### ğŸ‡ºğŸ‡¸ Tanabe pill delays blood disorder; enGene adds up to $100M from loans

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-21 16:25

> Plus, news about IO, ErVimmune, Affibody, Clasp Therapeutics and Infinitopes: ğŸ’Š Tanabe Pharmaâ€™s pill succeeds in rare blood conditions: The biotechâ€™s oral melanocortin-1 receptor delayed the onset of symptoms in a ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/tanabe-pill-delays-blood-disorder-engene-adds-up-to-100m-from-loans/)

---

### ğŸ‡ºğŸ‡¸ #JPM26: Regeneron, Lilly, Summit on rivals crowding into same targets

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-21 14:00

> There are countless diseases lacking a single good treatment, but drugmakers are still herding into the same targets, particularly in chasing after megablockbusters. George Yancopoulos, the outspoken co-founder and chief scientific officer of Regeneron, is ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/jpm26-regeneron-lilly-summit-on-rivals-crowding-into-same-targets/)

---

### ğŸ‡ºğŸ‡¸ Exclusive: Claim Health raises $4.4M to help home care providers get paid

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-21 14:00

> After an initial wave of AI startups that automated specific administrative tasks in healthcare, companies are now racing to handle the entire process. Claim Health, which aims to manage every step of how home care ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/exclusive-claim-health-raises-4-4m-to-help-home-care-providers-get-paid/)

---

### ğŸ‡ºğŸ‡¸ Think Bioscience gets $55M to unearth new drug pockets

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-21 12:00

> A Boulder, CO-based startup is searching for previously undiscovered footholds â€” not on rocks, but on molecules. Think Bioscience has raised a $55 million Series A led by investors including Regeneron Ventures ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/think-bioscience-gets-55m-to-unearth-new-drug-pockets/)

---

### ğŸ‡ºğŸ‡¸ EU Parliament adopts stricter drug stockpiling rules under Critical Medicines Act

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-20 18:55

> The European Parliament has adopted proposals aimed at reducing critical drug shortages across the EU, including stricter stockpiling rules and incentives for companies to boost manufacturing capacity. On Tuesday, the European Parliament adopted the Critical ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/eu-parliament-adopts-stricter-drug-stockpiling-rules-under-critical-medicines-act/)

---

### ğŸ‡ºğŸ‡¸ Valneva withdraws chikungunya vaccine from US

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-20 18:37

> Valneva has taken its chikungunya vaccine out of the US market, withdrawing its suspended product and a now-halted post-marketing study. The company said Monday that it decided to voluntarily withdraw its ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/valneva-withdraws-chikungunya-vaccine-from-us/)

---

### ğŸ‡ºğŸ‡¸ Clinician groups ask court to overturn CDC's childhood vaccine overhaul

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-20 15:54

> Leading clinician groups are asking a federal court to undo the US overhaul of the childhood vaccine schedule, calling the move the â€œmost egregious, reckless, and dangerousâ€ action that HHS Secretary Robert F. Kennedy Jr ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/clinician-groups-ask-court-to-overturn-cdcs-childhood-vaccine-overhaul/)

---

### ğŸ‡ºğŸ‡¸ Aspect Bio takes Novo castoff therapies; Takeda trims US jobs

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-20 14:58

> Plus, news about AstraZeneca, AbelZeta, Novavax, Pfizer, Alteogen, Tesaro, Epidarex Capital and Boundless Bio: ğŸ¤ Aspect Biosystems picks up Novo Nordiskâ€™s castoff cell therapies: The Vancouver biotech has taken over stem cell-derived islet cell and ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/aspect-bio-takes-novo-castoff-therapies-takeda-trims-us-jobs/)

---

### ğŸ‡ºğŸ‡¸ Teladocâ€™s mental health arm BetterHelp has quietly expanded the use of AI

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-20 13:00

> One of the largest virtual mental health companies has been warming up to using AI. Teladocâ€™s BetterHelp, which calls itself the worldâ€™s largest therapy service with over 32,000 therapists, now uses AI to recommend goals ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/teladocs-mental-health-arm-betterhelp-has-quietly-expanded-the-use-of-ai/)

---

### ğŸ‡ºğŸ‡¸ 2025 ended on high note with a buoyant Q4 for M&A, PIPEs and follow-ons

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-20 13:00

> After a downbeat start to 2025, biopharma struck some high notes in the second half and ended the year with strong Q4 momentum in dealmaking, fundraising and M&amp;A. The numbers, once again tracked for us ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/2025-ended-on-high-note-with-a-buoyant-q4-for-ma-pipes-and-follow-ons/)

---

### ğŸ‡ºğŸ‡¸ J&J, Isomorphic sign research deal for AI-made molecules

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-20 12:00

> The Google DeepMind spinout Isomorphic Labs has landed its third pharma deal. The AI-focused biotech has signed a multi-target research deal with Johnson &amp; Johnson, the two companies announced Tuesday. Isomorphic, founded in 2021 and ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/jj-isomorphic-sign-research-deal-for-ai-made-molecules/)

---

### ğŸ‡ºğŸ‡¸ JPM recap; Mirador raises $250M; Genentechâ€™s PBM shift; and more

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-17 11:00

> Welcome back to Endpoints Weekly! One programming note before we dive into news from #JPM26: We wonâ€™t be sending newsletters on Monday, but weâ€™ll be back in your inbox on Tuesday. The Endpoints News ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/jpm-recap-mirador-raises-250m-genentechs-pbm-shift-and-more/)

---

## ç›‘ç®¡å®¡æ‰¹ | Regulatory

### ğŸ‡ºğŸ‡¸ What's New Related to Drugs

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-21 22:55
- **é‡è¦æ€§**: â­â­

> Want to know what's new on drugs from FDA? This page provides quick links to the latest on a variety of topics including: drug approvals, safety warnings, drug shortages, etc.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/news-events-human-drugs/whats-new-related-drugs)

---

### ğŸ‡ºğŸ‡¸ Drug Trials Snapshots

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-21 22:45
- **é‡è¦æ€§**: â­â­

> Drug Trials Snapshots: breaking down the what, how and why. Drug Trials Snapshots is part of an overall FDA effort to make demographic data more available and transparent.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots)

---

### ğŸ‡ºğŸ‡¸ Importing Liquid Cough and Cold Medicine from India

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-21 17:56
- **é‡è¦æ€§**: â­â­

> FDA is aware of news reports of devastating, ongoing diethylene glycol (DEG) and ethylene glycol (EG) contamination in childrenâ€™s cough and cold medicine in India.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/human-drug-imports/importing-liquid-cough-and-cold-medicine-india)

---

### ğŸ‡ºğŸ‡¸ Drug Alerts and Statements

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-21 15:01
- **é‡è¦æ€§**: â­â­

> FDA Drug Alerts and Statements

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/drug-safety-and-availability/drug-alerts-and-statements)

---

### ğŸ‡ºğŸ‡¸ FDA Announces PreCheck Implementation Roadmap

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-21 15:00
- **é‡è¦æ€§**: â­â­

> The U.S. Food and Drug Administration announced that it will begin accepting applications on Feb. 1, 2026 for the PreCheck Pilot Program, a program to strengthen the domestic pharmaceutical supply chain. Learn more.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-precheck-implementation-roadmap)

---

### ğŸ‡ºğŸ‡¸ Drugs@FDA Data Files

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-21 14:19
- **é‡è¦æ€§**: â­â­

> Drugs@FDA Downloadable Data File in ZIP format, Data Definitions, and Entity Relationship Diagram (ERD)

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files)

---

### ğŸ‡ºğŸ‡¸ GDUFA IV: Fiscal Years 2028 â€“ 2032

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-20 21:42
- **é‡è¦æ€§**: â­â­

> Information related to FDAâ€™s preparation for the fourth reauthorization of GDUFA will be hosted on this page as it becomes available.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/industry/generic-drug-user-fee-amendments/gdufa-iv-fiscal-years-2028-2032)

---

### ğŸ‡ºğŸ‡¸ For Healthcare Professionals | FDAâ€™s Examples of Drugs that Interact with CYP Enzymes and Transporter Systems

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-20 19:55
- **é‡è¦æ€§**: â­â­

> FDAâ€™s Examples of Interacting Drugs and Other Substances Involving CYP Metabolic- and Transporter System-Based Pathways for Healthcare Professionals

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/drug-interactions-labeling/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems)

---

### ğŸ‡ºğŸ‡¸ Antimicrobial Resistance

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-20 17:18
- **é‡è¦æ€§**: â­â­

> Antimicrobial resistance (AMR)â€”the ability of a microorganism (bacteria, virus, fungi, parasite) to resist the effects of a drugâ€”is a serious, complex and costly public health problem. Learn what FDA is doing to address AMR.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/emergency-preparedness-and-response/mcm-issues/antimicrobial-resistance)

---

### ğŸ‡ºğŸ‡¸ Novel Drug Approvals for 2025

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-21 22:45

> Innovative drugs often mean new treatment options for patients and advances in health care for the American public.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)

---

### ğŸ‡ºğŸ‡¸ Drug Trials Snapshots KYGEVVI

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-21 22:43

> Drug Trials Snapshots KYGEVVI

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-kygevvi)

---

### ğŸ‡ºğŸ‡¸ Compounding Quality Center of Excellence | Instructor-Led Trainings

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-21 21:32

> The Compounding Quality Center of Excellenceâ€™s free in-person training programs target outsourcing facility staff and offer continuing education credits. The training will open for state regulators and pharmacy compounders if space is available.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/compounding-quality-center-excellence/compounding-quality-center-excellence-instructor-led-trainings)

---

### ğŸ‡ºğŸ‡¸ Generic Drug Facilities, Sites and Organization Lists

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-21 19:53

> Generic Drug Facilities, Sites and Organization Lists

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/industry/generic-drug-user-fee-amendments/generic-drug-facilities-sites-and-organization-lists)

---

### ğŸ‡ºğŸ‡¸ Quality and Regulatory Predictability: Shaping USP Standards - 12/11/2025

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-21 16:26

> This discussion will show how USP public standards strengthen quality, streamline development, support regulatory compliance, and overall, increase regulatory predictability for drugs.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/news-events-human-drugs/quality-and-regulatory-predictability-shaping-usp-standards-12112025)

---

### ğŸ‡ºğŸ‡¸ Recently Issued Guidance Documents

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-21 14:35

> This page lists Recently Issued CBER and Cross-Center Guidance Documents.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/vaccines-blood-biologics/biologics-guidances/recently-issued-guidance-documents)

---

### ğŸ‡ºğŸ‡¸ Information for Health Care Professionals | Drugs

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-21 14:19

> Drug Information for Health Care Professionals, including drug labeling and safety information.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/resources-drugs/information-health-care-professionals-drugs)

---

### ğŸ‡ºğŸ‡¸ M4Q(R2) The Common Technical Document for the Registration of Pharmaceuticals for Human Use: Quality

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-21 12:45

> M4Q(R2) The Common Technical Document for the Registration of Pharmaceuticals for Human Use: Quality

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/regulatory-information/search-fda-guidance-documents/m4qr2-common-technical-document-registration-pharmaceuticals-human-use-quality)

---

### ğŸ‡ºğŸ‡¸ CDER Small Business and Industry Assistance (SBIA) Learn

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-20 21:38

> SBIA Learn offers a variety of multimedia resources to provide information that is comprehensive, interactive, and easily accessible to small pharmaceutical business and industry.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/cder-small-business-industry-assistance-sbia/cder-small-business-and-industry-assistance-sbia-learn)

---

### ğŸ‡ºğŸ‡¸ Office of Study Integrity and Surveillance (OSIS) Workshop 2022: CDER Inspections of Good Laboratory Practice, Animal Rule, and Bioavailability/Bioequivalence Study Sites - 07/19/2022

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-20 21:32

> Office of Study Integrity and Surveillance (OSIS) Workshop 2022&amp;#58; CDERInspections of Good Laboratory Practice, Animal Rule, and Bioavailability/Bioequivalence Study Sites

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/news-events-human-drugs/office-study-integrity-and-surveillance-osis-workshop-2022-cder-inspections-good-laboratory-practice)

---

### ğŸ‡ºğŸ‡¸ The ABCs of Product-Specific Guidances | Audio Transcript

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-20 17:44

> PSGs help streamline generic drug product development, promoting timely approval of abbreviated new drug application, or ANDA, submissions and increasing drug competition, ultimately improving patient access to high quality and affordable medicines.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/development-approval-process-drugs/abcs-product-specific-guidances-audio-transcript)

---

## å•†ä¸šåŠ¨æ€ | Business/M&A

### ğŸ‡ºğŸ‡¸ Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-19 14:34
- **é‡è¦æ€§**: â­â­

> Decision introduces zolbetuximab for eligible patients in NHS Scotland

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/scottish-medicines-consortium-becomes-first-in-uk-to-adopt-new-precision-gastric-cancer-treatment/)

---

### ğŸ‡ºğŸ‡¸ AAX Biotech and Vascurie announce new neuro-oncology collaboration

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-20 12:41
- **é‡è¦æ€§**: â­

> The collaboration will help to advance a pipeline of antibody candidates

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/aax-biotech-and-vascurie-announce-new-neuro-oncology-collaboration/)

---

### ğŸ‡ºğŸ‡¸ Nxera Pharma reports positive results from phase 3 insomnia trial in South Korea

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-19 14:42
- **é‡è¦æ€§**: â­

> Company prepares marketing submission after treatment shows strong efficacy

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/nxera-pharma-reports-positive-results-from-phase-3-insomnia-trial-in-south-korea/)

---

### ğŸ‡ºğŸ‡¸ Sun Pharmaâ€™s Unloxcyt now available in US for advanced cutaneous squamous cell carcinoma

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-21 12:13

> More than 71% of patients treated with Unloxcyt achieved disease control

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/sun-pharmas-unloxcyt-now-available-in-us-for-advanced-cutaneous-squamous-cell-carcinoma/)

---

### ğŸ‡ºğŸ‡¸ Peter Llewellyn-Davies

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-21 12:02

> ARTCLINE appoints Peter Llewellyn-Davies as Chairman of its Supervisory Board

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/appointments/peter-llewellyn-davies/)

---

### ğŸ‡ºğŸ‡¸ Venner Shipley announces opening of new Bristol office

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-20 12:42

> The firm already has a number of offices across the UK and Europe

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/venner-shipley-announces-opening-of-new-bristol-office/)

---

### ğŸ‡ºğŸ‡¸ Ipsen announces new data on Dysport in neurological disease

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-15 12:55

> Dysport reduces muscle contractions by blocking the transmission of nerve impulses

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/ipsen-announces-new-data-on-dysport-in-neurological-disease/)

---

### ğŸ‡ºğŸ‡¸ Jurgen Berendsen

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-15 12:54

> Symeres has appointed Jurgen Berendsen as Chief Financial Officer (CFO).

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/appointments/jurgen-berendsen/)

---

### ğŸ‡ºğŸ‡¸ True colours

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-15 10:09

> The gold standard in spectroscopy

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/web_exclusives/true-colours/)

---


---

*Generated by Pharma Daily - åˆ¶è¯èµ„è®¯èšåˆç³»ç»Ÿ*

*2026-01-22 04:41:48*